Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction
Carlos G. Santos‐Gallego, Ariana P. Vargas-Delgado, Juan Antonio Requena-Ibáñez, Álvaro García‐Ropero, Donna Mancini, Sean Pinney, Frank Macaluso, Samantha Sartori, Mercè Roqué, Fernando Sabatel-Pérez, Anderly Rodriguez-Cordero, M. Urooj Zafar, Icilma Fergus, Farah Atallah-Lajam, Johanna Contreras, Cathleen Varley, Pedro Moreno, Vivian M. Abascal, Anuradha Lala, Ronald Tamler, Javier Sanz, Valentı́n Fuster, Juan J. Badimón
Topics & Concepts
EmpagliflozinEjection fractionMedicineCardiologyPlaceboHeart failureInternal medicineClinical endpointRandomized controlled trialDiabetes mellitusType 2 diabetesEndocrinologyAlternative medicinePathologyDiabetes Treatment and ManagementCardiovascular Function and Risk FactorsHyperglycemia and glycemic control in critically ill and hospitalized patients